Clinical Trial Update: A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL [Phase 1]

View source ↗

Summary

Phase 1 study evaluating FIT-CD19-CAR-T Cells for relapsed/refractory B-cell acute lymphoblastic leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• FIT-CD19-CAR-T Cells (CAR-T cell therapy targeting CD19)

Snippet

Sponsor: TriArm Therapeutics (Taiwan) Limited | Conditions: Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING